Tower Research Capital (TRC)’s Apollo Endosurgery, Inc. APEN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-6,069
Closed -$60K 6625
2023
Q1
$60K Buy
6,069
+2,574
+74% +$25.5K ﹤0.01% 2342
2022
Q4
$35K Buy
3,495
+3,231
+1,224% +$24.1K ﹤0.01% 2625
2022
Q3
$1K Sell
264
-8,386
-97% -$46.5K ﹤0.01% 5944
2022
Q2
$32K Buy
8,650
+8,579
+12,083% +$40.6K ﹤0.01% 3321
2022
Q1
$0 Buy
+71
New +$433 ﹤0.01% 6911
2021
Q4
Sell
-418
Closed -$4K 6825
2021
Q3
$4K Sell
418
-2,308
-85% -$19.8K ﹤0.01% 5037
2021
Q2
$22K Sell
2,726
-46,028
-94% -$316K ﹤0.01% 3825
2021
Q1
$269K Buy
48,754
+37,694
+341% +$186K ﹤0.01% 1758
2020
Q4
$37K Buy
+11,060
New +$29.1K ﹤0.01% 3408
2020
Q3
Sell
-7,105
Closed -$11K 5212
2020
Q2
$11K Buy
7,105
+6,939
+4,180% +$13.8K ﹤0.01% 3986
2020
Q1
$0 Hold
166
﹤0.01% 4183
2019
Q4
$0 Buy
166
+66
+66% +$191 ﹤0.01% 4624
2019
Q3
$0 Sell
100
-503
-83% -$1.59K ﹤0.01% 4664
2019
Q2
$2K Buy
+603
New +$2.15K ﹤0.01% 3350
2019
Q1
Sell
-1,033
Closed -$4K 4468
2018
Q4
$4K Buy
1,033
+486
+89% +$2.4K ﹤0.01% 3097
2018
Q3
$4K Sell
547
-656
-55% -$5.09K ﹤0.01% 3241
2018
Q2
$9K Buy
1,203
+1,100
+1,068% +$6.84K ﹤0.01% 2847
2018
Q1
$1K Sell
103
-5,054
-98% -$31.8K ﹤0.01% 3124
2017
Q4
$29K Buy
+5,157
New +$23.5K ﹤0.01% 1772
2017
Q2
Sell
-39
Closed 3650
2017
Q1
$0 Buy
+39
New +$496 ﹤0.01% 4141
2016
Q3
Sell
-18
Closed 4694
2016
Q2
$0 Buy
+18
New +$270 ﹤0.01% 5157
2014
Q3
Sell
-5
Closed -$1K 5017
2014
Q2
$1K Buy
+5
New +$1.59K ﹤0.01% 3797
2014
Q1
Sell
-21
Closed -$7K 5082
2013
Q4
$7K Buy
21
+19
+950% +$6.98K ﹤0.01% 3325
2013
Q3
$1K Buy
2
+1
+100% +$438 ﹤0.01% 4373
2013
Q2
$0 Buy
+1
New +$376 ﹤0.01% 3995

Tower Research Capital (TRC)'s APEN Position: Q2 2023 in Review

Tower Research Capital (TRC) sold out of Apollo Endosurgery, Inc. (APEN) in Q2 2023, closing a stake of 6,069 shares — an estimated $60K sold.

Tower Research Capital (TRC) first reported a position in APEN in Q2 2013 and held it in 25 quarters. The position peaked at $269K in Q1 2021. 0 funds tracked by Wall St. Rank hold APEN as of Q2 2023.

  • Tower Research Capital (TRC) reported no remaining Apollo Endosurgery, Inc. position as of Q2 2023 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 6,069 Apollo Endosurgery, Inc. shares in Q2 2023, an estimated $60K.
  • Tower Research Capital (TRC) first reported a position in Apollo Endosurgery, Inc. in Q2 2013 and held it in 25 quarters.
  • Tower Research Capital (TRC)'s Apollo Endosurgery, Inc. position peaked at $269K in Q1 2021.
  • 0 funds tracked by Wall St. Rank held Apollo Endosurgery, Inc. as of Q2 2023.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2023, filed 14 Aug 2023.